Nine months without recurrence signals something different is happening
Among the most feared diagnoses in oncology, recurrent glioblastoma has long resisted every therapeutic advance thrown at it — returning within weeks, claiming lives with near certainty. This month in Kanazawa, Japan, a South Korean biotech offered early evidence that an RNA-based gene therapy called RZ-001 may be capable of interrupting that grim trajectory, with several patients holding their disease at bay for six to nine months or more. The data are preliminary, drawn from only ten patients, but in a condition where months feel like years, even a signal of this kind carries weight.
- Recurrent glioblastoma kills most patients within months of returning, and no therapy has reliably changed that — making every credible new approach a matter of life and death urgency.
- RZ-001 cleared its first major safety threshold cleanly: ten treated patients, zero dose-limiting toxicities, zero Grade 4 or worse adverse events, with side effects largely attributable to the disease itself rather than the drug.
- Several patients experienced tumor control lasting beyond six months, and some past nine — a striking departure from a cancer that typically resurges in two to four weeks after prior treatment.
- The therapy works by engineering RNA to selectively trigger cell death inside tumor tissue, a mechanism distinct from immunotherapy approaches that have repeatedly failed in glioblastoma trials.
- Rznomics is expanding enrollment and extending follow-up, while its parallel liver cancer program just received FDA RMAT designation — signaling that regulators and the company alike see broader potential in this RNA editing platform.
A South Korean biotech presented early clinical data this month suggesting that an experimental RNA-based gene therapy may be capable of slowing the return of recurrent glioblastoma — one of the deadliest and most treatment-resistant brain tumors known. The drug, RZ-001, was the subject of interim Phase 1/2a findings delivered by neurosurgeon Dr. Chae-Yong Kim at the Asian Society for Neuro-Oncology Annual Meeting in Kanazawa, Japan on June 13th.
Ten patients had been enrolled and treated. The safety picture was clean: no dose-limiting toxicities, no Grade 4 or worse adverse events, and side effects that appeared tied to the underlying disease rather than the therapy itself. More striking was what happened to tumors in several patients — disease control extending past six months, and in some cases beyond nine. For a cancer that typically recurs within two to four months of prior treatment and carries a near-certain mortality, those numbers represent a meaningful deviation from the expected course.
RZ-001 operates through RNA trans-splicing ribozyme technology, a platform designed to express a therapeutic gene selectively inside tumor cells and trigger their death. It is a form of RNA-level gene editing — a relatively new frontier in oncology, and one that has not yet been tried successfully against glioblastoma, a disease that has defeated immunotherapy and most other modern approaches.
Rznomics, which listed on South Korea's KOSDAQ exchange in late 2025 and signed a research collaboration with Eli Lilly earlier that year, is pursuing the platform across two cancer indications. Its hepatocellular carcinoma program received FDA RMAT designation in May 2026, a regulatory status that can accelerate development and increase regulator engagement. The company plans to expand glioblastoma enrollment and continue long-term follow-up — cautious next steps in what remains, for now, an early but genuinely encouraging signal.
A South Korean biotech company presented early clinical evidence this month that an experimental RNA-based gene therapy can slow the return of one of the brain's most lethal cancers. The drug, called RZ-001, was tested in ten patients with recurrent glioblastoma—a tumor that typically comes back within two to four months and kills most people who develop it, even after aggressive surgery, radiation, and chemotherapy.
Dr. Chae-Yong Kim, a neurosurgeon at Seoul National University Bundang Hospital, delivered the interim findings on June 13th at the Asian Society for Neuro-Oncology Annual Meeting in Kanazawa, Japan. The data came from the first phase of a clinical trial designed to test both safety and early signs of whether the drug works. Twenty patients had been screened; ten had been enrolled and treated. What the researchers found was encouraging enough to warrant continued development: no serious unexpected side effects, no dose-limiting toxicities, and no Grade 4 or worse adverse events. The adverse events that did occur were mostly tied to the underlying disease itself, not the therapy.
What made the data noteworthy was not just the safety profile, but what happened to tumors in several patients. Some showed prolonged disease control—meaning the cancer did not grow back—for more than six months. A few extended that control past nine months. For a disease that typically recurs in weeks, that represents a meaningful departure from the natural history. Glioblastoma is one of the most aggressive malignant brain tumors known. Standard treatments have limited efficacy. Immunotherapy approaches, which have transformed treatment for many other cancers, have repeatedly failed in glioblastoma trials. The disease represents what researchers call an area of immense unmet medical need—a population of patients with few options and poor odds.
RZ-001 works through a proprietary platform called RNA trans-splicing ribozyme technology. The drug is engineered to express a therapeutic gene specifically inside tumor cells, triggering cancer cell death. It is a form of gene editing at the RNA level, a relatively new approach to cancer treatment. Rznomics, the company developing it, is a clinical-stage biotech based in South Korea. The company went public on the KOSDAQ market in December 2025 and signed a research collaboration with Eli Lilly in May 2025 to develop related RNA editing therapeutics.
Dr. Kim noted in his presentation that the extended disease control observed in some patients was particularly striking given what is known about glioblastoma's natural behavior. "Given that recurrent glioblastoma typically recurs within two to four months, the data from patients showing long-term recurrence inhibition—particularly that of extending past nine months—is highly encouraging," he said. He emphasized that the team plans to enroll more patients and conduct longer follow-up observations to determine the full clinical value of the approach.
RZ-001 is being developed for two cancer types. The glioblastoma program is in Phase 1/2a trials. A separate program targeting hepatocellular carcinoma—a common form of liver cancer—recently achieved a significant regulatory milestone: FDA designation as a Regenerative Medicine Advanced Therapy, or RMAT, in May 2026. That designation can accelerate development timelines and provide more frequent communication with regulators. The dual-indication strategy suggests the company believes its RNA editing platform has broader applicability beyond brain tumors. For now, the glioblastoma data represents an early signal that a new mechanism might offer hope to patients facing one of oncology's most intractable problems.
Citações Notáveis
Given that recurrent glioblastoma typically recurs within two to four months, the data from patients showing long-term recurrence inhibition—particularly that of extending past nine months—is highly encouraging.— Dr. Chae-Yong Kim, Seoul National University Bundang Hospital
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that some patients went nine months without recurrence when the typical window is two to four months?
Because in glioblastoma, time is everything. The disease is so aggressive that even a doubling of disease-free survival can change the trajectory of a patient's life—more time with family, more time for other treatments to be developed, more time to hope. Nine months is not a cure, but it is a signal that something different is happening.
What makes this RNA approach different from the immunotherapies that have failed in glioblastoma?
Immunotherapy tries to wake up the body's own immune system to attack the cancer. But glioblastoma is very good at hiding from the immune system. This therapy works differently—it goes directly into the tumor cell and edits its RNA to trigger cell death from within. It is a more direct mechanism.
The safety data shows no Grade 4 adverse events. Does that mean the drug is safe, or just that it hasn't hurt anyone yet?
It means it hasn't hurt anyone yet in this small group. Ten patients is a beginning, not an ending. But the fact that there were no unexpected safety signals and no dose-limiting toxicities is important—it means the researchers can keep going, can enroll more patients, can look for efficacy without being stopped by toxicity concerns.
Why is the FDA's RMAT designation for the liver cancer program significant?
It signals that regulators believe the platform has real potential. RMAT designation means faster communication with the FDA, potentially faster approval pathways. It also suggests the company's technology might work across different cancer types, not just brain tumors.
What happens next?
More patients get enrolled. The trial continues. Researchers follow people longer to see if disease control holds, if survival improves. In a year or two, there will be more data. That is when we will know if this early promise was real.